Technical Data
G8951-25M
Granulocyte Macrophage Colony Stimulating Factor, Recombinant, Mouse (GM-CSF, Colony-stimulating Factor, CSF, Colony Stimulating Factor 2 (Granulocyte-macrophage), Csf2, Csfgm, MGC151255, MGC151257, MGI-IGM)
2ug
|
Technical Data |
|
G8951-25M |
Granulocyte Macrophage Colony Stimulating Factor, Recombinant, Mouse (GM-CSF, Colony-stimulating Factor, CSF, Colony Stimulating Factor 2 (Granulocyte-macrophage), Csf2, Csfgm, MGC151255, MGC151257, MGI-IGM) |
2ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Source: Recombinant corresponding to 125aa of mouse Granulocyte Macrophage-Colony Stimulating Factor expressed in E.coli is a single, non-glycosylated, polypeptide chain. Molecular Weight: ~14.3kD Biological Activity: The ED50 as determined by the dose-dependent stimulation of the proliferation of mouse FDC-P1 cell line is less then 0.2ng/ml, corresponding to a Specific Activity of 5x10 6IU/mg. Dimmers and Aggregates: 1% (SDS-PAGE) Protein Content: Protein quantitation was carried out by two independent methods: 1.UV spectroscopy at 280nm using the absorbency value of 0.765 as the extinctioncoefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of GM-CSF as a Reference Standard. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: ~14.3kD |
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug) Concentration: Not determined Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. In vitro effector activity of Pneumocystis murina-specific T-cytotoxic-1 CD8+ T cells: role of granulocyte-macrophage colony-stimulating factor. Infect Immun 2005 Nov;73(11):7450-7. 2. Serum profiles of circulating granulocyte-macrophage colony-stimulating factor in acute myocardial infarction and relation with post-infarction left ventricular function. Chin Med J (Engl) 2005 Sep 20;118(18):1557-9. 3. Comparison of the activities of granulocyte-macrophage colony-stimulating factor and interleukin-8 secretion between two lung epithelial cell lines. J Microbiol Immunol Infect 2005 Oct;38(5):327-31. 4. Nonobese diabetic mouse congenic analysis reveals chromosome 11 locus contributing to diabetes susceptibility, macrophage STAT5 dysfunction, and granulocyte-macrophage colony-stimulating factor overproduction. J Immunol 2005 Oct 1;175(7):4561-5. 5. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating fact or vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 2005 Nov;19(11):1929-33. 6. [Granulocyte-macrophage colony-stimulating factor]. Nippon Rinsho 2005 Aug;63 Suppl 8:51-3.
|
||